MAIA Biotechnology, Inc. (MAIA)
NYSEAMERICAN: MAIA · Real-Time Price · USD
1.920
+0.120 (6.67%)
At close: Jul 1, 2025, 4:00 PM
1.900
-0.020 (-1.04%)
Pre-market: Jul 2, 2025, 8:00 AM EDT
MAIA Biotechnology Employees
MAIA Biotechnology had 13 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
13
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,515,728
Market Cap
58.19M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 13 | 0 | - |
Dec 31, 2023 | 13 | -5 | -27.78% |
Dec 31, 2022 | 18 | 9 | 100.00% |
Dec 31, 2021 | 9 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
MAIA News
- 23 hours ago - MAIA Biotechnology to Present Two Posters Featuring Cancer Telomere-Targeting Agents at FEBS 2025 Congress - Business Wire
- 8 days ago - MAIA Biotechnology Welcomes Leading Hepatocellular Carcinoma Clinician-Scientists to Scientific Advisory Board - Business Wire
- 13 days ago - MAIA Biotechnology Announces Master Clinical Supply Agreement with Roche for Hard-to-Treat Cancer Therapies - Business Wire
- 21 days ago - MAIA Biotechnology to Present at BIO International Convention 2025 - Business Wire
- 26 days ago - MAIA Biotechnology's Experimental Cancer Drug Shows Tripled Survival Vs. Standard Chemotherapy In Pretreated Lung Cancer Patients - Benzinga
- 26 days ago - MAIA Biotechnology Announces New Responder in Non-Small Cell Lung Cancer Phase 2 Clinical Trial - Business Wire
- 27 days ago - MAIA Biotechnology Announces Positive Efficacy Update for Phase 2 THIO-101 Clinical Trial in Non-Small Cell Lung Cancer - Business Wire
- 5 weeks ago - CORRECTING and REPLACING MAIA Biotechnology Announces Private Placement of Approximately $695,000 - Business Wire